Startups
CSL
Edit

CSL

Trusted
https://www.csl.com/
Last activity: 21.10.2026
Active
Categories: BioTechCareCommerceFutureHealthTechLocalMedTechReputation
Delivering on promises is what we do at CSL. More than a century ago, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotechnology company, that same promise has never been stronger.

We provide life-saving medicines in more than 60 nations with over 17,000 employees worldwide. CSL is driven to develop and deliver a broad range of life-saving medicines to treat disorders such as haemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.

Innovation has been in the DNA of CSL since our beginning in 1916 and continues as the core of everything we do today. Innovation spans our company — reflected in our 1,100 dedicated scientists who focus on solving patients’ unmet needs every day.

As a global leader, CSL collaborates and supports patient and medical communities by improving access to therapies, advancing scientific knowledge, supporting future medical researchers, and engaging our staff in the support of local communities.
Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want.

CSL has earned a reputation as a passionate yet responsible organization driven to care for patients and deliver on its commitments. Today, our future has never looked brighter.
Followers
64.97K
Website visits
48.7K /mo.
Mentions
47

Overview

Location
Australia, Victoria, Melbourne
Employees
10001+
Founded date
1916

Mentions in press and media 47

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Oct 6, 2026Alentis and CSL enter USD 1.6 billion partnership CSL and Alentis Therapeutics announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a rang...
Oct 5, 2026CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesAlentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today ann...
Sep 11, 2026Lancet Publication Marks Important Advance in Influenza Prevention for Older AdultsPhase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept. 11, 2026 /PRNewswire/ -- CSL Seqirus, a bu...
Jul 1, 2026Ipsen to acquire Memo Therapeutics for up to EUR 700 million French biopahram company Ipsen and Schlieren-based Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeu...
Jun 26, 2026CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European UnionRecommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal P...
Apr 24, 2026Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 BillionKurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ...
Feb 10, 2026Shares of Australian biotech major CSL plunge to 8-year low after CEO departure, weak earningsCSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it announced the exit of Paul McKenzie as chief...
Feb 9, 2026Memo Therapeutics enters into a collaboration with CSL Under the Collaboration and Option Agreement, Schlieren-based Memo Therapeutics AG (MTx) will develop recombinant polyclonal IgG products, leveraging its proprietary DROPZYLLA® technology platform for cloning human antibody repertoires and...
Feb 2, 20263 Ways Health Brands Can Design Digital Experiences That Users Won’t AbandonAccording to new research, nearly half of users ultimately abandon the digital health or wellness technologies they adopt. This startling finding reveals a major challenge amid the industry’s rapid growth. Health and wellness technologies a...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about CSL

When was CSL founded?

CSL was founded in 1916.

What has the press written about CSL?

Parsers VC has collected 47 articles mentioning CSL, among them “Alentis and CSL enter USD 1.6 billion partnership” (Oct 6, 2026) and “CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases” (Oct 5, 2026).

Is CSL still active?

Yes, CSL is active; its latest activity on Parsers VC dates from Oct 21, 2026.